Last Updated: August 3, 2026

FROVATRIPTAN SUCCINATE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Frovatriptan Succinate, and when can generic versions of Frovatriptan Succinate launch?

Frovatriptan Succinate is a drug marketed by Amneal Pharms Co, Glenmark Pharms Ltd, Leading, Pharmobedient, and Renata. and is included in five NDAs.

The generic ingredient in FROVATRIPTAN SUCCINATE is frovatriptan succinate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the frovatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Frovatriptan Succinate

A generic version of FROVATRIPTAN SUCCINATE was approved as frovatriptan succinate by GLENMARK PHARMS LTD on March 11^th, 2016.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for FROVATRIPTAN SUCCINATE?
What are the global sales for FROVATRIPTAN SUCCINATE?
What is Average Wholesale Price for FROVATRIPTAN SUCCINATE?

Summary for FROVATRIPTAN SUCCINATE

US Patents:	0
Applicants:	5
NDAs:	5

Paragraph IV (Patent) Challenges for FROVATRIPTAN SUCCINATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FROVA	Tablets	frovatriptan succinate	2.5 mg	021006	1	2011-03-09

US Patents and Regulatory Information for FROVATRIPTAN SUCCINATE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amneal Pharms Co	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	211292-001	Nov 6, 2018	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmobedient	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	202931-001	Aug 28, 2014		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glenmark Pharms Ltd	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	204730-001	Mar 11, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Leading	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	216998-001	Apr 16, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Renata	FROVATRIPTAN SUCCINATE	frovatriptan succinate	TABLET;ORAL	213891-001	Apr 6, 2022	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.